EMN Stock Analysis: Eastman Chemical | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 8.419m USD | 12M Return: 28.5% | US2774321002 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 84.5M
EPS Trend: -42.2%
Qual. Beats: 1
Rev. Trend: -68.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eastman Chemical Company (NYSE: EMN) is a U.S.-headquartered specialty materials company founded in 1920 and based in Kingsport, Tennessee. It has been publicly traded since its IPO in October 1993 and is classified within the Materials sector as a diversified chemicals producer, with a mid-cap market capitalization of approximately $8.3 billion.
The company operates through four reporting segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers. These segments collectively serve a broad set of end-markets, including transportation, personal care, wellness, food and feed, agriculture, building and construction, water treatment, energy, electronics, and medical/pharma applications. Its product portfolio spans specialty additives and solvents, copolyesters, cellulosic biopolymers, polyester films, olefin and acetyl derivatives, plasticizers, and cellulose acetate fibers used in filtration media (notably cigarette filters), textiles, and nonwoven materials.
As a diversified chemicals business, Eastmans revenue is tied to a mix of industrial cyclical demand (construction, automotive, durables) and more defensive consumer end-uses (personal care, consumables, filtration). Its Chemical Intermediates segment includes more commodity-oriented products such as olefins and solvents, which typically carry lower margins, while the specialty segments (Advanced Materials, Additives & Functional Products, and Fibers) are generally positioned for higher value-added, performance-driven applications.
- Cellulose acetate tow demand weakens on declining global cigarette consumption
- Advanced Materials margins lift on copolyester pricing and biopolymer demand growth
- Chemical Intermediates margins compress from ethylene feedstock volatility
| Net Income: 442.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.81 > 1.0 |
| NWC/Revenue: 15.96% < 20% (prev 17.60%; Δ -1.63% < -1%) |
| CFO/TA 0.06 > 3% & CFO 991.0m > Net Income 442.0m |
| Net Debt (4.53b) to EBITDA (1.27b): 3.56 < 3 |
| Current Ratio: 1.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.3m) vs 12m ago -0.77% < -2% |
| Gross Margin: 19.88% > 18% (prev 24.04%; Δ -4.16% > 0.5%) |
| Asset Turnover: 57.86% > 50% (prev 61.02%; Δ -3.16% > 0%) |
| Interest Coverage Ratio: 3.53 > 6 (EBIT TTM 749.0m / Interest Expense TTM 212.0m) |
| A: 0.09 (Total Current Assets 4.25b - Total Current Liabilities 2.84b) / Total Assets 15.4b |
| B: 0.66 (Retained Earnings 10.2b / Total Assets 15.4b) |
| C: 0.05 (EBIT TTM 749.0m / Avg Total Assets 15.3b) |
| D: 0.66 (Book Value of Equity 6.10b / Total Liabilities 9.25b) |
| Altman-Z'' = 3.78 = AA |
| DSRI: 1.07 (Receivables 1.36b/1.34b, Revenue 8.87b/9.29b) |
| GMI: 1.21 (GM 24.04% / 19.88%) |
| AQI: 0.99 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 0.95 (Revenue 8.87b / 9.29b) |
| TATA: -0.04 (NI 442.0m - CFO 991.0m) / TA 15.4b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of August 12, 2026, the stock is trading at USD 74.77 with a total of 628,856 shares traded. Over the past week, the price has changed by +1.18%, over one month by +11.25%, over three months by +1.31% and over the past year by +28.53%.
Current recommended Stop Loss: 69.00 (which is 7.7% or 2.8 ATR below the current price).
Eastman Chemical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy EMN.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.6 | 9.1% |
P/E Trailing = 19.1771
P/E Forward = 11.5075
P/S = 0.9497
P/B = 1.3859
P/EG = 0.6426
Revenue TTM = 8.87b USD
EBIT TTM = 749.0m USD
EBITDA TTM = 1.27b USD
Long Term Debt = 4.20b USD (from longTermDebt, last fiscal year)
Short Term Debt = 765.0m USD (from shortTermDebt, last quarter)
Debt = 5.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.53b USD (calculated: Debt 5.22b - CCE 691.0m)
Enterprise Value = 12.9b USD (8.42b + Debt 5.22b - CCE 691.0m)
Interest Coverage Ratio = 3.53 (Ebit TTM 749.0m / Interest Expense TTM 212.0m)
EV/FCF = 24.02x (Enterprise Value 12.9b / FCF TTM 539.0m)
FCF Yield = 4.16% (FCF TTM 539.0m / Enterprise Value 12.9b)
FCF Margin = 6.08% (FCF TTM 539.0m / Revenue TTM 8.87b)
Net Margin = 4.99% (Net Income TTM 442.0m / Revenue TTM 8.87b)
Gross Margin = 19.88% ((Revenue TTM 8.87b - Cost of Revenue TTM 7.10b) / Revenue TTM)
Gross Margin QoQ = 22.28% (prev 19.80%)
Tobins Q-Ratio = 0.84 (Enterprise Value 12.9b / Total Assets 15.4b)
Interest Expense / Debt = 4.06% (Interest Expense 212.0m / Debt 5.22b)
Taxrate = 17.66% (95.0m / 538.0m)
NOPAT = 616.7m (EBIT 749.0m * (1 - 17.66%))
Current Ratio = 1.50 (Total Current Assets 4.25b / Total Current Liabilities 2.84b)
Debt / Equity = 0.86 (Debt 5.22b / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = 3.56 (Net Debt 4.53b / EBITDA 1.27b)
Debt / FCF = 8.40 (Net Debt 4.53b / FCF TTM 539.0m)
Total Stockholder Equity = 5.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.88% (Net Income 442.0m / Total Assets 15.4b)
RoE = 7.42% (Net Income TTM 442.0m / Total Stockholder Equity 5.96b)
RoCE = 7.37% (EBIT 749.0m / Capital Employed (Equity 5.96b + L.T.Debt 4.20b))
RoIC = 4.78% (NOPAT 616.7m / Invested Capital 12.9b)
WACC = 7.02% (E(8.42b)/V(13.6b) * Re(9.30%) + D(5.22b)/V(13.6b) * Rd(4.06%) * (1-Tc(0.18)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.42 | Cagr: -1.10%
[DCF] Terminal Value 77.97% ; FCFF base≈487.0m ; Y1≈558.3m ; Y5≈821.6m
[DCF] Fair Price = 68.56 (EV 12.4b - Net Debt 4.53b = Equity 7.84b / Shares 114.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -42.21 | EPS CAGR: -8.19% | SUE: 1.28 | # QB: 1
Revenue Correlation: -68.00 | Revenue CAGR: -2.09% | SUE: 2.43 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.96 | Chg30d=+1.80% | Revisions=-30% | Analysts=12
EPS current Year (2026-12-31): EPS=6.39 | Chg30d=+1.20% | Revisions=-36% | GrowthEPS=+17.9% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=6.93 | Chg30d=-0.07% | Revisions=-50% | GrowthEPS=+8.5% | GrowthRev=+1.8%
[Analyst] Revisions Ratio: -48% (up=5, down=17)